Diabetes drug semaglutide may boost blood vessel repair cells, small study hints

NCT ID NCT04126603

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This completed phase 4 trial tested whether semaglutide (a GLP-1 agonist drug) can improve the health of blood vessel repair cells and fat stem cells in people with type 2 diabetes. Ten participants received either semaglutide or a placebo for 24 weeks. Researchers measured changes in stem cell numbers, movement, and gene activity, as well as body composition and artery stiffness. The goal was to see if semaglutide could protect blood vessels and promote weight loss beyond its blood sugar effects.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Semaglutide (a GLP-1 receptor agonist drug)
What this could lead to
If it works, this could show that semaglutide helps protect blood vessels and improve fat cell function in people with type 2 diabetes, potentially reducing heart disease risk.
What could go wrong
This is a very small, early-phase trial (only 10 participants completed) looking at cell markers, not clinical outcomes. Results may not translate to real-world benefits, and the drug has known side effects like nausea and vomiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The GW Medical Faculty Associates

    Washington D.C., District of Columbia, 20037, United States

  • Washington VA Medical Center

    Washington D.C., District of Columbia, 20422, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.